The FDA has added a new label warning to weight loss drugs such as Wegovy. Tap through for what the warning covers.
Recap by typeshit. Full story at www.polskieradio.pl.
One study cited by @fittrwithsquats put the risk of non-scarring hair loss about 40% higher with GLP-1 use, mostly telogen effluvium. Nail findings are less consistent.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
A look at the effectiveness of oral Wegovy for weight loss, following the US approval of the daily pill version of semaglutide.
A Facebook roundup lines up CagriSema's REIMAGINE 2 numbers, with time in range rising from 52.3% to 88.0% by week 68, next to retatrutide's TRIUMPH-2 results.
Loading…